title: Clearance of BRAF inhibitor-associated keratoacanthomas by systemic retinoids.
authors.affiliation: Department of Dermatology, Phlebology and Allergology, Hospital Bremerhaven-Reinkenheide, Postbrookstraße 103, 27574, Bremerhaven, Germany. michael.sachse@klinikum-bremerhaven.de.
authors.forename: M M
authors.initials: MM
authors.lastname: Sachse
authors.forename: G
authors.initials: G
authors.lastname: Wagner
mesh_terms: D000368:Aged; D000077556:Alitretinoin; D000970:Antineoplastic Agents / Q000009:adverse effects; D005260:Female; D005542:Forearm; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D007636:Keratoacanthoma / Q000139:chemically induced / Q000188:drug therapy*; D008545:Melanoma / Q000188:drug therapy; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors; D012176:Retinoids / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy; D013449:Sulfonamides / Q000009:adverse effects*; D014212:Tretinoin / Q000627:therapeutic use*; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D012176:Retinoids; D013449:Sulfonamides; D000077556:Alitretinoin; D000077484:Vemurafenib; D014212:Tretinoin; D048493:Proto-Oncogene Proteins B-raf